Illumina (NASDAQ:ILMN) Insider Scott Davies Sells 323 Shares

Illumina, Inc. (NASDAQ:ILMN) insider Scott Davies sold 323 shares of Illumina stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider directly owned 17,887 shares in the company, valued at $2,434,241.83. The trade was a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Illumina Price Performance

Shares of ILMN traded down $3.36 during mid-day trading on Tuesday, reaching $131.56. The company had a trading volume of 1,767,767 shares, compared to its average volume of 2,126,404. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The company has a market capitalization of $20.10 billion, a P/E ratio of 29.50, a P/E/G ratio of 2.41 and a beta of 1.44. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $153.06. The company’s 50-day moving average is $115.39 and its 200-day moving average is $103.24.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.18. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The firm’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ILMN. Capital World Investors increased its stake in shares of Illumina by 20.0% in the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after buying an additional 3,331,542 shares during the period. State Street Corp boosted its holdings in Illumina by 6.8% in the third quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock valued at $569,800,000 after acquiring an additional 382,520 shares during the last quarter. WCM Investment Management LLC increased its position in Illumina by 5.9% in the second quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock worth $419,585,000 after purchasing an additional 247,460 shares during the period. Loomis Sayles & Co. L P raised its holdings in Illumina by 1.9% during the 2nd quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock worth $403,158,000 after purchasing an additional 78,317 shares during the last quarter. Finally, Corvex Management LP raised its holdings in Illumina by 125.2% during the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock worth $303,841,000 after purchasing an additional 2,129,449 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Robert W. Baird set a $109.00 price objective on shares of Illumina in a report on Friday, October 31st. JPMorgan Chase & Co. increased their price target on Illumina from $105.00 to $130.00 and gave the stock a “neutral” rating in a research report on Monday. Barclays raised their price target on Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a report on Monday. Royal Bank Of Canada set a $124.00 price objective on Illumina in a research report on Tuesday, September 2nd. Finally, Zacks Research upgraded Illumina from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $117.19.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.